First Trust NASDAQ Smart Grid ETF vs uniQure N.V. Ordinary Shares — how do they compare? First Trust NASDAQ Smart Grid ETF trades at $173.79 (market cap $12.09B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: First Trust NASDAQ Smart Grid ETF is far larger — about 8.2× uniQure N.V. Ordinary Shares's market cap, and First Trust NASDAQ Smart Grid ETF is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ Smart Grid ETF for 14 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| GRID | QURE | |
|---|---|---|
Market Cap | $12.09B | $1.48B |
Volume | 561,107 | 2,488,780 |
Sector | Sector/Thematic | Health |
52-Week High | $199.80 | $70.59 |
52-Week Low | $146.51 | $9.03 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | — | $728.62M |
Signals from Pluang's Aura AI — not financial advice
GRID trades at $179.25, up 0.31% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock is positioned in the smart grid infrastructure sector, benefiting from AI-driven power buildout investments. Recent news highlights its exposure to infrastructure modernization and AI energy demand, though key financial ratios are not disclosed in the provided data.
Outlook is mixed: technicals suggest caution, but thematic tailwinds from AI infrastructure spending offer growth potential. Risks include sector competition and execution challenges. Investors should weigh near-term technical weakness against long-term infrastructure investment trends.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
First Trust NASDAQ Smart Grid Infrastructure ETF seeks to track companies involved in smart grid and electricity infrastructure. Its holdings include businesses related to power networks, energy management, and grid technologies.
Read more on GRID →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →